Status:
UNKNOWN
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
Lead Sponsor:
Sichuan University
Collaborating Sponsors:
Geneplus-Beijing Co. Ltd.
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-70 years
Brief Summary
This study is designed to evaluate the untreated NSCLC patients. After participants have accepted chemotherapy, radiotherapy, and immunotherapy, the investigators used the next generation sequence tec...
Detailed Description
Lung cancer was one of the most deadly tumors in the world. The standard of care for patients is platinum-based doublet chemotherapy concurrent with radiotherapy. As for patients with a mutant epiderm...
Eligibility Criteria
Inclusion
- Pathologically verified stage IV non-small cell lung cancer without treated.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Major organs function normally
- Women at pregnant ages should be under contraception
- Willing and able to provide informed consent
Exclusion
- Pathology is mixed type•
- Poor vasculature
- Coagulopathy, or ongoing thrombolytics and/or anticoagulation
- Blood-borne infectious disease, e.g. hepatitis B
- History of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician
- Other conditions requiring exclusion deemed by physician
Key Trial Info
Start Date :
November 23 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03373955
Start Date
November 23 2017
End Date
December 31 2021
Last Update
March 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041